Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldesleukin - Clinigen/Novartis

Next Previous
X
Search
Drug Profile

Aldesleukin - Clinigen/Novartis

Alternative Names: 125-L-Serine-2-133-interleukin 2; Chiron IL-2; IL-2; IL-2 - Chiron; Interleukin-2 - Chiron; Macrolin™; Proleukin; r-serHuIL-2; Recombinant IL-2; Recombinant-human-interleukin-2 - Chiron; T cell growth factor

Latest Information Update: 01 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiron
  • Developer Hyup Jin Corporation; Ligand Pharmaceuticals; Merck Sharp & Dohme Corp.; National Cancer Institute (USA); Novartis; Prometheus Laboratories; University of Washington
  • Class Antiallergics; Antihyperglycaemics; Antineoplastics; Immunotherapies; Interleukins; Mood stabilisers; Recombinant proteins
  • Mechanism of Action Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders; Renal cell carcinoma; Non-Hodgkin's lymphoma; Malignant melanoma; Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma; Renal cell carcinoma
  • Phase II Amyotrophic lateral sclerosis
  • Discontinued HIV-1 infections; Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Aug 2023 Prometheus Laboratories, University of Washington, National Cancer Institute and Merck Sharp & Dohme Corp. terminates a phase I trial for Renal cell carcinoma (Metastatic disease, Late-stage disease, Combination therapy, Second line therapy or greater) in USA (SC) (IV) due to insufficient funding (NCT03260504)
  • 08 Dec 2022 Safety and pharmacodynamics data from a phase IIb MIROCALS trial in Amyotrophic lateral sclerosis released by Clinigen
  • 28 Sep 2021 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top